Adds details throughout
Dec 11 (Reuters) - Candel Therapeutics CADL.O said on Wednesday its experimental immunotherapy for prostate cancer met the main goal of a late-stage trial, helping the company's shares more than double in value in premarket trading.
The immunotherapy, CAN-2409, in combination with radiation therapy significantly improved disease-free survival in patients, compared to radiation alone, the company said.
Candel said it plans to discuss with the Food and Drug Administration regarding the therapy in intermediate-to-high-risk localized prostate cancer.
Over 100,000 men are diagnosed with prostate cancer every year in the U.S., the company said.
The company's shares were up 176.8% at $12.76 in trading before the bell.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Sriraj Kalluvila)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.